Champions Oncology Reports Quarterly Revenue of $8.8 Million

Jul 29, 2020 2:57:35 PM / by ManagingTeam

Record Annual Revenue of $32.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 27, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2020.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $9.0 Million

Mar 19, 2020 4:45:15 PM / by ManagingTeam

HACKENSACK, NJ / ACCESSWIRE / March 12, 2020 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the third fiscal quarter ended January 31, 2020.

Read More →

The Children’s Cancer Therapy Development Institute is Collaborating with Champions Oncology and Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services

Jan 29, 2020 10:00:00 AM / by Champions Oncology

The Children’s Cancer Therapy Development Institute (cc-TDI), Champions Oncology, and The Jackson Laboratory offer rapid, cost-effective services to the pharma, biopharma and biotech industry– speeding the right drug to the right pediatric cancer whenever possible.

Read More →

Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development

Nov 13, 2019 10:00:00 AM / by Champions Oncology

Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.

Read More →

Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations

May 30, 2019 10:00:00 AM / by Champions Oncology

HACKENSACK, NJ – May 30, 2019  –  Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

Sep 13, 2018 10:00:00 AM / by Champions Oncology

Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019

 Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.

Read More →

Champions Oncology Granted Full Accreditation by the AAALAC

Aug 8, 2018 8:30:17 AM / by Paul McGarry

Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.  AAALAC commended Champions for the quality and dedication of the staff, the superior quality of the animal facilities, the excellent program of veterinary medical care, and the highly knowledgeable and conscientious Institutional Animal Care and Use Committee.

Read More →

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

Jul 27, 2018 9:53:44 AM / by Paul McGarry

Expects Revenue Growth of at Least 20% for Fiscal Year 2019

Hackensack, NJ – July 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2018.

Read More →

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Jun 18, 2018 5:25:35 PM / by Cindy Lanzendoen

Hackensack, NJ – June 18, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.

Read More →

Champions Oncology to Present at the 3rd Annual Disruptive Growth & Healthcare Conference on May 9th

May 3, 2018 9:27:54 AM / by Paul McGarry

HACKENSACK, N.J., - May 3, 2018 - Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am. The conference is being hosted by RHK Capital and ReedSmith LLP, at Reed Smith’s offices located at 599 Lexington Avenue.

Read More →